Effekte, Bedingungen und Anwendung von Placebos

Kernaussagen

Placeboeffekte sind nicht nur eine Störgröße in wissenschaftlichen Wirksamkeitsuntersuchungen, sondern auch eine nicht zu vernachlässigende Wirkkomponente in Interventionen. Die Übersichtsarbeit stellt exemplarisch dar, unter welchen Bedingungen Placeboeffekte auftreten und wie diese in der klinischen Praxis berücksichtigt und ggf. genutzt werden könnten.

Publication History

Publication Date:
08 March 2016 (online)

• Literatur

• 1 Pepper OHP. A note on the placebo. Ann J Pharm 1945; 117: 409-412
• 2 Beecher HK. The powerful placebo. J Am Med Assoc 1955; 159: 1602-1606
• 3 Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet 2015; 385: 1502-1503
• 4 Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602
• 5 Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2010; 1: CD003974
• 6 Levine JD, Gordon NC, Fields HL. The mechanism of placebo analgesia. Lancet 1978; 312: 654-657
• 7 de la Fuente-Fernandez R, Ruth TJ, Sossi V. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001; 293: 1164-1166
• 8 Lidstone SC, Schulzer M, Dinelle K. et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch Gen Psychiatry 2010; 67: 857-865
• 9 Brunoni AR, Lopes M, Kaptchuk TJ. et al. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PloS One 2009; 4: e4824
• 10 Benedetti F, Lanotte M, Colloca L. et al. Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti-parkinsonian placebo response. J Physiol 2009; 587: 3869-3883
• 11 Kaptchuk TJ, Kelley JM, Deykin A. et al. Do “placebo responders” exist?. Contemp Clin Trials 2008; 29: 587-595
• 12 Peciña M, Azhar H, Love TM. et al. Personality trait predictors of placebo analgesia and neurobiological correlates. Neuropsychopharmacol 2013; 38: 639-646
• 13 Darragh M, Booth RJ, Consedine NS. Investigating the ‘placebo personality’outside the pain paradigm. J Psychosom Res 2014; 76: 414-421
• 14 Hall KT, Lembo AJ, Kirsch I. et al. Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 2012; 7: e48135
• 15 Finniss DG, Kaptchuk TJ, Miller F. et al. Biological, clinical, and ethical advances of placebo effects. Lancet 2010; 375: 686-695
• 16 Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 1996; 64: 535-543
• 17 Scott DJ, Stohler CS, Egnatuk CM. et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008; 65: 220-231
• 18 Mayberg HS, Silva JA, Brannan SK. et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737
• 19 Rief W, Nestoriuc Y, von Lilienfeld-Toal A. et al. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis. Drug Safety 2009; 32: 1041-1056
• 20 Kessner S, Sprenger C, Wrobel N. et al. Effect of oxytocin on placebo analgesia: a randomized study. J Am Med Assoc 2013; 310: 1733-1735
• 21 Jensen KB, Petrovic P, Kerr CE. et al. Sharing pain and relief: neural correlates of physicians during treatment of patients. Mol Psychiatry 2014; 19: 392-398
• 22 Enck P, Bingel U, Schedlowski M. et al. The placebo response in medicine: minimize, maximize or personalize?. Nat Rev Drug Discov 2013; 12: 191-204
• 23 Moseley JB, O'Malley K, Petersen NJ. et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347: 81-88
• 24 Fournier JC, DeRubeis RJ, Hollon SD. et al. Anti-depressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 2010; 303: 47-53
• 25 Gaab J, Blease C, Locher C. et al. Go open: A plea for transparency in psychotherapy. Psychology of Consciousness: Theory, Research, and Practice 2015;
• 26 Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?. J Dev Behav Pediatr 2010; 31: 369-375
• 27 Doering BK, Rief W. Utilizing placebo mechanisms for dose reduction in pharmacotherapy. Trends Pharmacol Sci 2012; 33: 165-172
• 28 Sandler A, Glesne C, Geller G. Children’s and parents’ perspectives on open-label use of placebos in the treatment of ADHD. Child Care Health Dev 2008; 34: 111-120
• 29 Kaptchuk TJ, Friedlander E, Kelley JM. et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One 2010; 5: e15591
• 30 Fässler M, Meissner K, Schneider A. et al. Frequency and circumstances of placebo use in clinical practice – a systematic review of empirical studies. BMC Med 2010; 8: 15
• 31 Howick J, Bishop FL, Heneghan C. et al. Placebo use in the United Kingdom: results from a national survey of primary care practitioners. PLoS One 2013; 8: e58247